Australia Sets New Minimum Pay, Insurance Rules for Gig Workers 
Oil Prices Rise as US-Iran Talks Stall, Inflation Risks Grow 
Asian Stocks Mixed as RBA Holds Rates, Oil Risks Rise 
Bill Ackman’s Pershing Square Returns to Netflix With Major New Stake 
Natura Q2 Profit Plunges 92% as Financial Expenses Weigh on Earnings 
KOSPI Rebounds 20% as Samsung, SK Hynix Lead South Korea Stock Rally 
UK Economy Posts Surprise June Growth as World Cup and Hot Weather Lift Activity 
Trump Weighs Capital Gains Tax Cuts Ahead of Midterms 
Hims & Hers Shares Fall as GLP-1 Costs Widen Q2 Loss 
European Stocks Rise as U.S. Inflation Data Eases Fed Rate Hike Fears 
Singapore Raises 2026 GDP Growth Forecast to 4.5%-5.5% as AI Boom Fuels Economy 
Samsung, SK Hynix Shares Surge on Report of Potential Temasek Investment 
ADNOC Gas Targets Up to $4B Profit in 2026 
US Dollar Holds Firm as Fed Outlook and Iran Tensions Keep Markets on Edge 
OpenAI Executive Brad Lightcap to Leave for New AI Venture 
England Drought Expands to 71% as Heatwave Deepens Water Crisis 
Asian Currencies Steady Ahead of US CPI as Oil Prices Rise 
Add as a preferred source on Google
Sanofi, a pharmaceutical company headquartered in Paris, France, announced its acquisition of the American biopharmaceutical firm, Kadmon. It was revealed that the deal is worth $1.9 billion and the French drugmaker made the purchase to further strengthen the growth of its transplant business line.
Sanofi shared the news about its latest acquisition on Wednesday, Sept. 8. The firm confirmed its purchase of Kadmon Holdings just a month after buying Translate BIO, another US-based biotech company for $3.2 billion.
According to Reuters, Sanofi offered to buy Kadmon in cash at $9.50 per share which is equivalent to more or less $1.9 billion. It was mentioned that both of the firms’ boards did not oppose the deal and granted approval for the deal to proceed.
“We are transforming and simplifying our General Medicines business and have shifted our focus on differentiated core assets in key markets,” Sanofi’s executive vice president of general medicines, Olivier Charmeil, said in a press release. “We are thrilled to add Kadmon's Rezurock to our well-established transplant portfolio. Our existing scale, expertise, and relationships in transplant create an ideal platform to achieve the full potential of Rezurock, which will address the significant unmet medical needs of patients with chronic graft-versus-host disease around the world.”
On the other hand, Kadmon’s president and chief executive officer, Harlan Waksal, M.D., said that they were thrilled as Sanofi acknowledged the value of its Rezurock oral medicine for GVHD or chronic graft versus host disease, a crippling immune-mediated condition that affects many blood cancer patients who underwent bone marrow transplants.
He added that by making use of the pharmaceutical company’s global resources and well-known expertise in developing and selling new medicines, Rezurock is now in a better position for international accessibility. Kadmon’s Rezurock is a drug for the treatment of both adults and patients who are 12 years and older. It was approved by the U.S. Federal Drug Administration (FDA) in July.
Finally, with Sanofi’s acquisition of Kadmon, the said medicine will now become the French pharma company’s third drug under its transplant medicine business. This is also its third major purchase in this year alone.
